UBM announces plans for pharma and bio events in Japan

Published: 31-Mar-2010

Growth in events stimulated by Japanese pharma sector changes

Reflecting the growth in interest in the fine chemicals, pharmaceuticals and biopharma industries in the second largest pharma market in the world, event organiser UBM International Media and sister company UBM Japan Co. Ltd have announced details of the highlights of their 2010 Japanese Pharma events. CPhI Japan, supported by ICSE Japan, P-MEC Japan and featuring a dedicated BioPharma Pavilion, will take place from 21 – 23 April at Tokyo’s Big Sight Exhibition Center, providing wide coverage and great networking opportunities across all the main pharma services sectors.

UBM’s Japanese events have expanded steadily, stimulated by dynamic changes in the Japanese pharmaceutical market such as the revision of Japan’s pharmaceutical law, growing competition from foreign companies, increased merger and acquisition activity and the rise in demand for generic drugs. With an estimated annual value of US$60bn (b bn), Japan’s pharmaceutical market will constitute approximately 11% of the total world market in 2010.

CPhI Japan, launched in 2002, is the biggest pharmaceutical ingredients exhibition held in Japan. The 2010 event features more than 130 seminars and exhibition presentations, including keynote sessions from Dr Akihisa, Chief Scientist of Pfizer Japan Inc., who will focus on ‘R&D Strategies for the Next Generation’ and Marc Dunoyer, Vice Chairman of EFPIA Japan and Representative Director & Chairman, GlaxoSmithKline K.K., who will discuss ‘Reducing the Drug Lag’.

One highlight for 2010 is expected to be the BioPharma Pavilion, which made its debut during CPhI Japan 2009. For 2010, it has been extended, reflecting the increasing convergence of pharma and biotech business models in global healthcare, and the growing numbers of biopharma partnerships in drug innovation, production and market delivery.

‘With the biopharma industry assuming greater prominence in Japan for several reasons – not least the country’s aging population and the Government’s increased focus on the generics market as it bids to keep medical expenses under control – Japanese pharmaceutical manufacturers are eager to catch up with competitors from the US and Europe and are seeking to do so through investment and co-operation with bio-ventures and universities,’ commented Eliane van Doorn, UBM International Media’s Group Director for Pharma events.

‘In addition, the Japanese government has been investing in developing the domestic ‘bio-infrastructure’ through funding bio-industrial cluster projects and setting up support programmes for bio-ventures and universities to enhance Japan’s biopharma industry. The BioPharma pavilion at CPhI Japan presents an ideal platform, therefore, for the Japanese biopharma industry to meet potential new partners from foreign countries.’

Mirroring the significant growth in the demand for contract services in the Japanese market, the ICSE Pavilion provides a unique opportunity to present new products, outsourcing solutions or r&d development to the Japanese pharmaceutical audience.

P-MEC Japan, with its focus on Pharma machinery and equipment, is rapidly evolving to embrace every aspect of pharma and biotech equipment and technology, from packaging machinery, through laboratory and analytical techniques, to track and trace technologies.

You may also like